RPL18: Potential Therapeutic Targets for Telomere Lengthening

Target Name: RPL18

NCBI ID: G6141

RPL18

RPL18: Potential Therapeutic Targets for Telomere Lengthening

RPL18 (retinoblastoma-like 18) is a gene that encodes a protein known as RPL18, which is a key regulator of the length of telomeres, the protective caps at the end of chromosomes. Telomeres are repetitive DNA sequences that protect the ends of chromosomes from degradation, fusion, and other forms of damage. In humans, telomeres are naturally shortened each time a cell divides, and the shortest telomeres are usually cut off after about 50-70 times cell division. This process is known as \"telomere exhaustion\" and is a hallmark of aging and age-related diseases.

The discovery of RPL18 and its function as a regulator of telomere length has significant implications for our understanding of the aging process and potential therapeutic interventions. RPL18 has also been implicated in a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. As such, it is a promising target for drug development.

The Protein encoded by RPL18

RPL18 encodes a protein that is composed of 218 amino acids. The protein has a molecular weight of 23.9 kDa and a pre-fusion calculated pI of 6.9 angstroms. It is expressed in most tissues of the body and is primarily localized to the nucleoplasm. RPL18 is also known to be a nuclear protein, which means it is primarily localized to the nucleus of cells.

The functions of RPL18

RPL18 is involved in the regulation of telomere length and the aging process. It is a key regulator of the telomere-replication complex (TRC), which is responsible for copying the telomeres to the opposite ends of the chromosomes before each cell divides. RPL18 is required for the TRC to function properly and for telomeres to be properly shortened and cut off.

In addition to its role in telomere regulation, RPL18 is also involved in the regulation of DNA replication, transcription, and other cellular processes. It has been shown to play a role in the regulation of cell cycle progression, and is required for the proper functioning of the cell cycle.

The link between RPL18 and aging

RPL18 is highly expressed in tissues of older animals, and its levels are decreased in tissues of older humans. This age-related decline in RPL18 expression has been linked to the shortening of telomeres and the aging process. As telomeres become shorter, the ability of cells to divide and replicate becomes limited, leading to an aging process.

In addition to its role in aging, RPL18 has also been implicated in a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, studies have shown that RPL18 is often expressed in tissues of individuals with cancer, and that it may play a role in the development and progression of these diseases.

The Potential therapeutic uses of RPL18

The discovery of RPL18 as a potential drug target has significant implications for the treatment of a variety of diseases. One of the primary targets for RPL18 is the regulation of telomere length, which is a key factor in the aging process. The shortening of telomeres has been linked to a variety of age-related diseases, including cancer, neurodegenerative diseases, and developmental disorders. As such, drugs that can lengthen telomeres may have therapeutic benefits in these diseases.

In addition to its potential role in treating age-related diseases, RPL18 may also be a useful target for diseases that are characterized by the over-expression of repetitive DNA sequences. For example, RPL18 has

Protein Name: Ribosomal Protein L18

Functions: Component of the large ribosomal subunit (PubMed:12962325, PubMed:23636399, PubMed:25957688, PubMed:25901680, PubMed:32669547). The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell (PubMed:12962325, PubMed:23636399, PubMed:25957688, PubMed:25901680, PubMed:32669547)

The "RPL18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets